Engineering nanoparticle strategies for effective cancer immunotherapy

Hong Yeol Yoon, Subramanian Tamil Selvan, Yoosoo Yang, Min Ju Kim, Dong Kee Yi, Ick Chan Kwon, Kwang Meyung Kim

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Cancer immunotherapy has been emerging in recent years, due to the inherent nature of the immune system. Although recent successes of immunotherapeutics in clinical application have attracted development of a novel immunotherapeutics, the off-target side effect and low immunogenicity of them remain challenges for the effective cancer immunotherapy. Theranostic nanoparticle system may one of key technology to address these issues by offering targeted delivery of various types of immunotherapeutics, resulting in significant improvements in the tumor immunotherapy. However, appropriate design or engineering of nanoparticles will be needed to improve delivery efficiency of antigen, adjuvant and therapeutics, resulting in eliciting antitumor immunity. Here, we review the current state of the art of cancer immunotherapeutic strategies, mainly based on nanoparticles (NPs). This includes NP-based antigen/adjuvant delivery vehicles to draining lymph nodes, and tumor antigen-specific T-lymphocytes for cancer immunotherapy. Several NP-based examples are shown for immune checkpoint modulation and immunogenic cell death. These overall studies demonstrate the great potential of NPs in cancer immunotherapy. Finally, engineering NP strategies will provide great opportunities to improve therapeutic effects as well as optimization of treatment processes, allowing to meet the individual needs in the cancer immunotherapy.

Original languageEnglish
Pages (from-to)597-607
Number of pages11
JournalBiomaterials
Volume178
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Immunotherapy
Nanoparticles
Antigens
Neoplasms
Tumors
T-cells
Immune system
Neoplasm Antigens
Therapeutic Uses
Cell death
Immune System
Immunity
Cell Death
Lymph Nodes
Modulation
Technology
T-Lymphocytes
Therapeutics

Keywords

  • Adjuvant delivery
  • Antigen delivery
  • Immune checkpoint
  • Immunotherapy
  • Nanoparticles

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Yoon, H. Y., Selvan, S. T., Yang, Y., Kim, M. J., Yi, D. K., Kwon, I. C., & Kim, K. M. (2018). Engineering nanoparticle strategies for effective cancer immunotherapy. Biomaterials, 178, 597-607. https://doi.org/10.1016/j.biomaterials.2018.03.036

Engineering nanoparticle strategies for effective cancer immunotherapy. / Yoon, Hong Yeol; Selvan, Subramanian Tamil; Yang, Yoosoo; Kim, Min Ju; Yi, Dong Kee; Kwon, Ick Chan; Kim, Kwang Meyung.

In: Biomaterials, Vol. 178, 01.09.2018, p. 597-607.

Research output: Contribution to journalArticle

Yoon, Hong Yeol ; Selvan, Subramanian Tamil ; Yang, Yoosoo ; Kim, Min Ju ; Yi, Dong Kee ; Kwon, Ick Chan ; Kim, Kwang Meyung. / Engineering nanoparticle strategies for effective cancer immunotherapy. In: Biomaterials. 2018 ; Vol. 178. pp. 597-607.
@article{6a88e2a772df4ae8b3ccc04ec9ebd2f8,
title = "Engineering nanoparticle strategies for effective cancer immunotherapy",
abstract = "Cancer immunotherapy has been emerging in recent years, due to the inherent nature of the immune system. Although recent successes of immunotherapeutics in clinical application have attracted development of a novel immunotherapeutics, the off-target side effect and low immunogenicity of them remain challenges for the effective cancer immunotherapy. Theranostic nanoparticle system may one of key technology to address these issues by offering targeted delivery of various types of immunotherapeutics, resulting in significant improvements in the tumor immunotherapy. However, appropriate design or engineering of nanoparticles will be needed to improve delivery efficiency of antigen, adjuvant and therapeutics, resulting in eliciting antitumor immunity. Here, we review the current state of the art of cancer immunotherapeutic strategies, mainly based on nanoparticles (NPs). This includes NP-based antigen/adjuvant delivery vehicles to draining lymph nodes, and tumor antigen-specific T-lymphocytes for cancer immunotherapy. Several NP-based examples are shown for immune checkpoint modulation and immunogenic cell death. These overall studies demonstrate the great potential of NPs in cancer immunotherapy. Finally, engineering NP strategies will provide great opportunities to improve therapeutic effects as well as optimization of treatment processes, allowing to meet the individual needs in the cancer immunotherapy.",
keywords = "Adjuvant delivery, Antigen delivery, Immune checkpoint, Immunotherapy, Nanoparticles",
author = "Yoon, {Hong Yeol} and Selvan, {Subramanian Tamil} and Yoosoo Yang and Kim, {Min Ju} and Yi, {Dong Kee} and Kwon, {Ick Chan} and Kim, {Kwang Meyung}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.biomaterials.2018.03.036",
language = "English",
volume = "178",
pages = "597--607",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Engineering nanoparticle strategies for effective cancer immunotherapy

AU - Yoon, Hong Yeol

AU - Selvan, Subramanian Tamil

AU - Yang, Yoosoo

AU - Kim, Min Ju

AU - Yi, Dong Kee

AU - Kwon, Ick Chan

AU - Kim, Kwang Meyung

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Cancer immunotherapy has been emerging in recent years, due to the inherent nature of the immune system. Although recent successes of immunotherapeutics in clinical application have attracted development of a novel immunotherapeutics, the off-target side effect and low immunogenicity of them remain challenges for the effective cancer immunotherapy. Theranostic nanoparticle system may one of key technology to address these issues by offering targeted delivery of various types of immunotherapeutics, resulting in significant improvements in the tumor immunotherapy. However, appropriate design or engineering of nanoparticles will be needed to improve delivery efficiency of antigen, adjuvant and therapeutics, resulting in eliciting antitumor immunity. Here, we review the current state of the art of cancer immunotherapeutic strategies, mainly based on nanoparticles (NPs). This includes NP-based antigen/adjuvant delivery vehicles to draining lymph nodes, and tumor antigen-specific T-lymphocytes for cancer immunotherapy. Several NP-based examples are shown for immune checkpoint modulation and immunogenic cell death. These overall studies demonstrate the great potential of NPs in cancer immunotherapy. Finally, engineering NP strategies will provide great opportunities to improve therapeutic effects as well as optimization of treatment processes, allowing to meet the individual needs in the cancer immunotherapy.

AB - Cancer immunotherapy has been emerging in recent years, due to the inherent nature of the immune system. Although recent successes of immunotherapeutics in clinical application have attracted development of a novel immunotherapeutics, the off-target side effect and low immunogenicity of them remain challenges for the effective cancer immunotherapy. Theranostic nanoparticle system may one of key technology to address these issues by offering targeted delivery of various types of immunotherapeutics, resulting in significant improvements in the tumor immunotherapy. However, appropriate design or engineering of nanoparticles will be needed to improve delivery efficiency of antigen, adjuvant and therapeutics, resulting in eliciting antitumor immunity. Here, we review the current state of the art of cancer immunotherapeutic strategies, mainly based on nanoparticles (NPs). This includes NP-based antigen/adjuvant delivery vehicles to draining lymph nodes, and tumor antigen-specific T-lymphocytes for cancer immunotherapy. Several NP-based examples are shown for immune checkpoint modulation and immunogenic cell death. These overall studies demonstrate the great potential of NPs in cancer immunotherapy. Finally, engineering NP strategies will provide great opportunities to improve therapeutic effects as well as optimization of treatment processes, allowing to meet the individual needs in the cancer immunotherapy.

KW - Adjuvant delivery

KW - Antigen delivery

KW - Immune checkpoint

KW - Immunotherapy

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85052002908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052002908&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2018.03.036

DO - 10.1016/j.biomaterials.2018.03.036

M3 - Article

C2 - 29576282

AN - SCOPUS:85052002908

VL - 178

SP - 597

EP - 607

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -